Member Info for alfista

Always ready to misread posts to create a neverhopeful slant.

ByHealth have submitted for BlueCap registration based on the health claim that has almost 15years of EFSA approval, with full human trials. IF approved, they should be able to launch immediately, given their huge spend to date.

The human trials gixer mentioned are for yet another novel health claim.

But then you knew that.

The strong PR campaign continues, ByHealth clearly give great significance to Fruitflow in their near term plans.

However, somehow the platelet aggregation theme is hard to get in to mass psyche, the masses aren't tuned in to how vital bloodflow is to all health IMHO. If anyone can crack the education on this function, ByHealth have the resources.

Few folks are buying the shares on anticipation any more, the market needs firm news.

The billionaire investor may be amused to be regarded as retail.

Apologies GKP'ers, I have no idea how that came to be posted here, clearly it was intended for another board.

Very clear from the latest webinar that an impressive team has been built. David Hobbs is now established as the main man, Jay's role has diminished somewhat, and that is as it should be IMHO. From Bob, as the man that first identified the asset, to the drilling and regulatory experts tasked with developing the strategy, there is real industry excellence. The backer is also crucial, his involvement put the skids under Mangrove's strategy. They appeared to be relying on drip feeding lies and distortions to execute their short, The company has responded with facts and figures, with financial muscle to counter the attack. The market has liked this, and soon the drill will be turning again, and folks looking forward to the results, expecting that the improved team will achieve the results they were employed to deliver

The next phase is highly important, as it puts in place the information required ahead of the final investment decision. There are still doubters, and no doubt they will put their money where their mouth is, as will those who see this as an improving scenario based on all the information from the company to date

Very clear from the latest webinar that an impressive team has been built. David Hobbs is now established as the main man, Jay's role has diminished somewhat, and that is as it should be IMHO. From Bob, as the man that first identified the asset, to the drilling and regulatory experts tasked with developing the strategy, there is real industry excellence. The backer is also crucial, his involvement put the skids under Mangrove's strategy. They appeared to be relying on drip feeding lies and distortions to execute their short, The company has responded with facts and figures, with financial muscle to counter the attack. The market has liked this, and soon the drill will be turning again, and folks looking forward to the results, expecting that the improved team will achieve the results they were employed to deliver

The next phase is highly important, as it puts in place the information required ahead of the final investment decision. There are still doubters, and no doubt they will put their money where their mouth is, as will those who see this as an improving scenario based on all the information from the company to date

Indeed.

If the auditors are seeing something they are not happy about, it's time they told the market.

If everything is as happy clappy as the company insists, that's fine and dandy.

Let's be knowing

Yep. Just about the worst thing that can happen to a human short of the obvious.

I really hope that this is as significant as it appears.

This is a medical intervention treatment. A drug.

It's very interesting that massive doses have a direct influence on sufferers of this horrendous condition.

I hope that the human trials can follow and that a life enhancing benefit can be added to the growing list.

Obviously, that would bring a financial gain, but I'm more excited over the possibility of such a breakthrough medically.

A possible explanation of your PR comments are that you are in the business in the US, and you have the hump because you didn't get the gig. Personally, I wouldn't employ you to create a shopping list, your PR are skills are sub zero.

Groan !!!

DSM are applying for new IP patents regarding gut health.

We HAVE been informed of that.

Years away from commercial products appearing.

Your wish to have the last word is a bit tiring.

Not so.

If there was something of significance financially, then the company has a duty to report that to the market.

You know how these things work, you've been around long enough.

If it was "bolted on" then it wouldn't be this price.

Would it.

Especially on the holding he took at sub .30

Don't see why DP should be abused for his view. Although it is optimistic, large volume increases created by the type of aggressive marketing which has enabled ByHealth's stellar growth could feasible support that kind of valuation. It would create the circumstances where a sizeable dividend could attract the type of value buyers looking for a good return,

Added to that, if DSM's IP registration for gut health becomes a commercial reality would certainly add considerably more value.

As an aim, I'm not sure, I have the feeling that many a long termer would have exited long before, but it will be news driven, as always. No news leaves us down at these levels, we are data starved, relying only on the excellent info provided by gixer. He's a star.

Are we toe understand that you only ever bought the once Naz? You never had any other investment cash over all the year, so you never took advantage when the sp was much lower than today's? You never took account of all the advances over the years, and the significant support gained from HNW investors?

Just bought the once and then determined to keep muttering about it for the rest of your days?

Should have stuck with the post office account perhaps.

All you need to do is look at the balance sheet of Provexis, their spend is listed. The make an assumption based on that for what DSM and ByHealth have spent. Arguably, the total is higher.

The BlueCap registration only seems to refer to the original IP claimed by Provexis, so the R&D to prove up and register all the other claims will require ongoing R&D spend.

Not cheap passing all regulations for a worldwide/multi health claim nutraceutical product.

Nobody saw all of this in 2009, and the wild enthusiasm in that period was based around Fruitflow being the first ever approval of the EFSA. The sp was manipulated by someone, hence the "No Reason" RNS which killed it off. We'll never know the whole story, pointless to keep digging it up.

I think you are echoing market sentiment in those views.

We know the order size would be a step change over what has been produced before, with the obvious funding requirement, which could be met in several ways.

We know that the margin on existing sales will be much higher, but we don't know how much extra cost of servicing demand is. Profit now? Not sure myself.

We know that gut health is a massive market, but we don't know what early commercialisation means, especially given the glacial pace of developments to date.

Those are known unknowns, will any other unknown unknowns appear? We didn't see the other IP novelties coming. What we need is Fruitflow disappearing down gullets worldwide, and lots of it.

No, I could trawl through all of your posts and highlight the consistent lies you have posted. Plain lies, all in support of short positions also based on lies. You ought to be made to pay for them, but the company is letting expert reports be their answer, so you are lucky

Not correct, I have called you Looey, which is phonetically correct, and Lulu, which is a nickname. Whereas you have corrupted my username in a disgusting manner.